Contraception - barrier methods and spermicides
Exam Tips
- Remember efficacy gap: male condom ~98% perfect use vs ~82% typical use; female condom ~95% perfect vs ~79% typical.
- Cervical cap effectiveness is lower in parous than nulliparous users; this is a classic SBA discriminator.
- Diaphragms/caps must be used with spermicide and left in for at least 6 hours after sex.
- Condoms (male and female) reduce STI transmission; diaphragms/caps provide little STI protection.
- Nonoxinol-9 safety point: repeated use can damage genital epithelium and may increase HIV transmission risk in high-risk populations.
- Image reference for viva/OSCE revision: review pelvic placement diagrams of female condom, diaphragm, and cervical cap in standard SRH anatomy atlases (device position relative to cervix is frequently tested).
Definition
Barrier contraception is a non-hormonal method that prevents fertilization by physically blocking sperm from reaching the cervix, and in the case of condoms also reducing exchange of genital secretions. In UK practice this includes male condoms, female condoms (Femidom), diaphragms, and cervical caps; diaphragms and caps require concurrent spermicide to improve contraceptive effect.
Pathophysiology
Male and female condoms create a mechanical barrier that limits exposure to ejaculate, pre-ejaculate, and cervicovaginal secretions, which is why they reduce both pregnancy risk and many STI risks when used consistently and correctly. Diaphragms and cervical caps sit over the cervix, reducing sperm entry into the uterine cavity; spermicide (nonoxinol-9) adds a chemical spermicidal effect by disrupting sperm cell membranes. Because caps/diaphragms do not cover all genital mucosa, STI protection is limited compared with condoms. Repeated high-frequency exposure to nonoxinol-9 can disrupt genital epithelium, increasing mucosal vulnerability and potentially increasing HIV acquisition/transmission risk in high-risk groups.
Risk Factors
- Inconsistent or incorrect use at each act of intercourse (major contributor to typical-use failure)
- Poor condom fit, breakage, or slippage
- Incorrect insertion or displacement of female condom, diaphragm, or cap
- Parous status for cervical cap users (higher failure than in nulliparous users)
- Not using spermicide with diaphragm/cap
- Use of nonoxinol-9 spermicides in people at high STI/HIV risk
- Latex allergy limiting use of latex male condoms or some diaphragms
- Postpartum period <6 weeks or <6 weeks after second-trimester termination for diaphragm/cap use
Clinical Features
Symptoms
- Usually asymptomatic in routine contraceptive use
- Unintended pregnancy concern after breakage/slippage or incorrect use
- Genital irritation or burning (latex or spermicide sensitivity)
- Dyspareunia or discomfort with inner ring (female condom) or with cap/diaphragm
- Possible recurrent lower urinary symptoms in some diaphragm users
Signs
- No abnormal examination findings in uncomplicated use
- Contact vulvovaginitis/erythema if local sensitivity occurs
- Features of STI if exposed and unprotected by effective barrier use
Investigations
Management
Lifestyle Modifications
- Provide method-specific teaching and demonstration: correct condom application/removal, checking expiry and integrity, and single-use only
- Advise dual protection when STI risk exists (condom plus another contraceptive method)
- For male latex condoms, use water- or silicone-based lubricant; avoid oil-based products that can weaken latex
- For female condoms (polyurethane), oil-based lubricants are acceptable
- For diaphragm/cap users, ensure fitting support where needed; leave in place for at least 6 hours after intercourse
- Reassess diaphragm/cap fit after childbirth and after weight change of about 3 kg or more
- Discuss emergency contraception if unprotected intercourse or method failure occurs
Pharmacological Treatment
Spermicide
- Nonoxinol-9 vaginal spermicide (Gygel)
Used with diaphragm or cervical cap to increase contraceptive efficacy. Apply intravaginally before intercourse and reapply for each subsequent act as per product instructions. Safety warning: frequent/high-dose nonoxinol-9 may cause epithelial irritation/lesions and is not advised for people at high HIV/STI risk; condoms pre-lubricated with nonoxinol-9 are not recommended.
Complications
- Unintended pregnancy from method or user failure
- STI/HIV acquisition if relying on methods with limited STI protection (especially cap/diaphragm)
- Latex or spermicide-related genital irritation/allergic reactions
- Condom breakage, slippage, or incorrect use
- Increased urinary tract infection tendency in some diaphragm users due to urethral pressure
- Reduced acceptability/adherence due to interruption of intercourse or discomfort
Prognosis
Barrier methods are safe, reversible, and immediately effective when used correctly, with no delay in return to fertility after stopping. Real-world pregnancy prevention is lower than with long-acting reversible contraception because effectiveness depends on technique and consistency. Condoms remain the key barrier option for STI risk reduction; outcomes improve markedly with structured counseling on fit and correct use.
Sources & References
✅NICE Guidelines(1)
📖Textbook References(4)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1701)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1709, 1710)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1710)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 80)[context]